Related Experiment Video
Updated: Aug 11, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
Drug-related lupus. Incidence, mechanisms and clinical implications
1Department of Internal Medicine, University of Cincinnati Medical Center, Ohio.
Abstract:
Adverse side effects to drugs and chemicals in which immune mechanisms may be responsible have been described in drug-related lupus (DRL). The spectrum of drugs that may elicit DRL includes such classes as the hydrazines, arylamines, and chemicals that can be metabolised to amines. The 2 major pathways of metabolism--acetylation and N-hydroxylation--are described in detail. The events leading to autoantibody production are not well understood; however, specific consideration of the genetic makeup of patients who are candidates for treatment with these drugs may help identify those at risk of developing DRL.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Drug Toxicity: Risk factors
Drug Toxicity: Dose-Dependent Reactions
Drug Toxicity: Allergic Reactions
Drug toxicity: Idiosyncratic Reactions
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

